PFIZER, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.66 USD | +1.63% |
|
-0.10% | -0.45% |
| 31/05 | Sector Update: Health Care Stocks Higher Late Afternoon | MT |
| 31/05 | Sector Update: Health Care Stocks Advance Friday Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows:
- primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.;
- specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.;
- oncology products (12.1%);
- other (1.3%).
At the end of 2022, the group had more than 35 manufacturing sites worldwide.
Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
28.2
USD
Average target price
31.92
USD
Spread / Average Target
+13.18%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -0.45% | 160B | |
| +40.73% | 734B | |
| +32.83% | 591B | |
| -6.30% | 350B | |
| +15.15% | 315B | |
| +4.05% | 276B | |
| +15.00% | 238B | |
| +9.78% | 206B | |
| -5.52% | 204B | |
| +6.17% | 161B |
- Stock Market
- Equities
- PFE Stock
- News Pfizer, Inc.
- Pfizer Says Phase 3 Trial of Abrysvo for Respiratory Syncytial Virus Disease Meets Primary Endpoints
